|
Patient characteristics in naïve and experienced groups |
||||
| Charactertistic |
Antiretroviral naïve (N = 155) |
Antiretroviral experienced (N = 883) |
||
|
|
||||
| (quantitative) |
Mean |
SD |
Mean |
SD |
|
|
||||
| Age (years) |
38.86 |
6.47 |
38.91 |
5.44 |
| Nadir CD4+ (cells/μl) |
185.02 |
115.79 |
159.99 |
131.80 |
| CD4+ T-cell count at baseline (cells/μl) |
206.75 |
133.53 |
357.88 |
233.05 |
| HIV-RNA at baseline (copies/ml) |
177,480 |
252,619 |
53,615 |
168,410 |
| ALT at baseline (x10 IU/l) |
6.94 |
4.14 |
7.13 |
4.42 |
| AST at baseline (x10 IU/l) |
6.27 |
3.88 |
5.87 |
3.94 |
| CD4+ T-cell slope (cells/μl) |
107.86 |
116.37 |
44.30 |
149.48 |
| Exposure to DDX-drugs at baseline (days) |
- |
- |
1,288 |
1,075 |
|
|
||||
| (qualitative) |
N |
% |
N |
% |
|
|
||||
| Gender (male) |
113 |
72.90 |
677 |
76.67 |
| Risk factor for HIV acquisition (former IVDU) |
105 |
67.74 |
684 |
77.46 |
| HBsAg positivity |
15 |
10.27 |
55 |
6.48 |
| HDVAb positivity |
4 |
2.96 |
25 |
2.83 |
| Previous grade ≥III LFT elevation |
15 |
9.68 |
317 |
35.90 |
| Previous treatment with IFN |
7 |
4.52 |
72 |
8.15 |
| Concurrent use of DDX-drugs |
50 |
32.26 |
526 |
59.57 |
| Concurrent use of 3TC |
138 |
89.03 |
618 |
69.99 |
| Concurrent use of TDF |
17 |
18.97 |
136 |
15.40 |
|
|
||||
| Treatment group (Single PI) |
32 |
20.64 |
202 |
22.88 |
|
|
||||
| NFV |
27 |
84.38 |
147 |
72.77 |
| IDV |
2 |
6.25 |
32 |
15.84 |
| SQV |
3 |
9.37 |
19 |
9.41 |
| Others |
- |
- |
4 |
1.98 |
|
|
||||
| Treatment group (Multiple PI) |
50 |
32.26 |
322 |
36.47 |
|
|
||||
| LPV/r |
42 |
84 |
175 |
54.35 |
| IDV/r |
5 |
10 |
83 |
25.78 |
| SQV/r |
1 |
2 |
48 |
14.91 |
| Others |
2 |
4 |
16 |
4.96 |
|
|
||||
| Treatment group (NNRTI) |
73 |
47.10 |
359 |
41.62 |
|
|
||||
| EFV |
42 |
57.53 |
165 |
45.96 |
| NVP |
31 |
42.47 |
194 |
54.04 |
|
The following abbreviations were used: SD = standard deviation; ALT = alanine amino-transferase, AST = aspartate amino-transferase; DDX = dideoxy-nucleoside analogue drugs (i.e., didanosine, stavudine, zalcitabine); IVDU = intra-venous drug use; IFN = interferon; 3TC = lamivudine, TDF = tenofovir disoproxil fumarate; PI = protease inhibitor, NFV = nelfinavir, IDV = indinavir, SQV = saquinavir, LPV/r = lopinavir/ritonavir, IDV/r = indinavir/ritonavir; SQV/r = saquinavir/ritonavir; NNRTI = non nucleoside reverse transcriptase inhibitor, EFV = efavirenz, NVP = nevirapine. The following variables were different between drug naive and experienced patients at univariate comparison: nadir CD4+ T-cell count (P: 0.027), CD4+ T-cell count at baseline (P < 0.001), HIV-RNA at baseline (P < 0.001), CD4+ T-cell slope (P: <0.001), risk factor for HIV acquisition (P: 0.009), previous LFT elevation grade ≥III (P < 0.001), concurrent use of DDX-drugs (P < 0.001), concurrent use of 3TC (P < 0.001), use of IDV as single PI (P: 0.002), use of LPV/r (P: 0.04) or SQV/r (P: 0.009) as multiple PI, use of EFV as NNRTI (P: 0.016). CD4+ T-cell slope was available for 146 patients in naïve group and for 844 patients in experienced group; HBsAg status was available for 146 patients in naive group and for 848 patients in experienced group; HDVAb status was available for 135 patients in naive group and for 833 patients in experienced group. | ||||
Torti et al. BMC Infectious Diseases 2005 5:58 doi:10.1186/1471-2334-5-58 |
||||